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Every year in the US, 20,000 new primary and nearly 200,000metastatic brain tumor cases
are reported. The cerebral microvessels/capillaries that form the blood–brain barrier not
only protect the brain from toxic agents in the blood but also pose a signiﬁcant hindrance
to the delivery of small and large therapeutic molecules. Different strategies have been
employed to circumvent the physiological barrier posed by blood–brain tumor barrier
(BTB). Studies in our laboratory have identiﬁed signiﬁcant differences in the expression
levels of certain genes and proteins between normal and brain tumor capillary endothelial
cells (ECs). In this study, we validated the non-invasive and clinically relevant dynamic
contrast enhancing-magnetic resonance imaging (DCE-MRI) method with invasive,
clinically irrelevant but highly accurate quantitative autoradiographymethod using rat glioma
model. We also showed that DCE-MRI metric of tissue vessel perfusion-permeability
is sensitive to changes in blood vessel permeability following administration of
calcium-activated potassium (BKCa) channel activator NS-1619. Our results show that
human gliomas and brain tumor ECs that overexpress BKCa channels can be targeted for
increased BTB permeability for MRI enhancing agents to brain tumors. We conclude that
monitoring the outcome of increased MRI enhancing agents’ delivery to microsatellites
and leading tumor edges in glioma patients would lead to beneﬁcial clinical outcome.
Keywords: blood–brain barrier, blood–brain tumor barrier, drug delivery, brain tumors, metastatic brain tumor,
potassium channels, DCE-MRI, biochemical modulation of BTB
INTRODUCTION
A signiﬁcant number of primary tumor cases are reported each
year in the US, and the metastatic tumors from systemic cancers
are at least 10-fold higher than the primary brain tumors. The
magnitude of the problem at the global level is even more stag-
gering. Estimates show that about 50% of patients receiving brain
radiation and/or surgical resection have recurrences in the brain
within a year, severely shortening life expectancy (Ningaraj, 2006).
Targeting gliomas is extremely difﬁcult because brain provides a
“safe haven” for tumor cells. The cerebral microvessels/capillaries
that form the blood–brain barrier (BBB) block the delivery of most
small and large therapeutic molecules (Pardridge, 2003). Differ-
ent strategies have been employed to circumvent the physiological
barrier posed by blood–brain tumor barrier (BTB), often based on
a conception of the barrier being controlled by the “neurovascular
unit”consisting of endothelial cells (ECs), tight junctional proteins
connecting the ECs, glial, pericytes, and astrocytic foot processes,
all of which interact with neurons (Quencer and Neuwelt, 2002;
Toda, 2003; Zhang et al., 2003; Pardridge, 2004; Rautioa and
Chikhale, 2004; Rich and Bigner, 2004; Kinoshita et al., 2006; Lee
et al., 2006). However, research should be focused on individual
component of the neurovascular unit. The focus is nowon targeted
cancer therapy by supplementing conventional chemotherapy and
radiotherapy with monoclonal antibodies (MAbs; Checkley et al.,
2003; Rich and Bigner, 2004; Khaitan et al., 2006; Buie and Valgus,
2008; Mathieu et al., 2008). The purpose of antibody treatment
of cancer is to induce the direct or indirect destruction of cancer
cells, either by speciﬁcally targeting either the tumor or the tumor
vasculature (Checkley et al., 2003; Buie and Valgus, 2008). Target-
ing tumor and tumor blood vessel-speciﬁc marker(s) is a good
strategy to control tumor growth (Ningaraj et al., 2003a). It is,
however, critical to studywhether tumor-speciﬁc drug delivery has
the potential to minimize toxicity to normal tissues, and improve
bioavailability of cytotoxic agents to neoplasms. Although the
BTB is “leaky” in the tumor center, the established microvessels
feeding the proliferating glioma edge as well as the brain tissue
surrounding the tumor are nearly as impermeable as the BBB (Ina-
mura and Black, 1994; Liu et al., 2001, 2002; Ningaraj et al., 2002,
2003a,b, 2009a,b; Black and Ningaraj, 2004, 2006, 2007; Khaitan
et al., 2009). It is incorrect to assume that the disrupted BBB facil-
itates drug delivery to gliomas because diffuse tumor cell invasion
is a hallmark of even low-grade gliomas.
Drug delivery research focuses on several innovative methods,
including nanoparticles, microparticles as carriers of anticancer
agents, polyethylene glycol (PEG) technology, encapsulating anti-
cancer drugs in liposomes, andMAbs for the delivery of anticancer
payloads (Ningaraj et al., 2007). One area of research has focused
on brain microvascular ECs (BVEC), which are a major compo-
nent of the neurovascular unit. However, many issues that are
related to BVEC are still not well understood, including gene
and protein proﬁling in normal brain and brain tumor capil-
lary ECs (Cucullo et al., 2003; Doubrovin et al., 2003; Demeule
et al., 2004; Kemper et al., 2004; Jaeger et al., 2005). Research in
this ﬁeld is hampered due to the complexities that are involved
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in isolating pure BVEC devoid of pericytes, neurons, and tumor
cell populations, as well as due to differences between and within
brain tumors. For instance, signiﬁcant differences were found
between normal human brain and brain tumor capillaries, includ-
ing differential expression of large conductance calcium-activated
potassium (BKCa) channels (Ningaraj et al., 2002, 2003a; Son-
theimer, 2004; Black and Ningaraj, 2006, 2007; Ningaraj, 2006;
Khaitan et al., 2009). Recent progress in the molecular target-
ing of tumor-speciﬁc antigens with speciﬁc agents, however, can
be exploited by identifying additional novel targets for modulat-
ing BTB permeability. Studies in our laboratory are investigating
whether any signiﬁcant differences exist in the expression levels
of certain genes and proteins or presence of unique molecules
in brain tumor capillary ECs that can be modiﬁed for increased
anticancer drug delivery to brain tumors (Ningaraj et al., 2002,
2003a,b; Black and Ningaraj, 2006, 2007; Khaitan et al., 2009).
The amount of drug that reaches at the tumor site depends on
BTB permeability, which varies considerably among brain tumor
patients (Fortin et al., 2005). Drug concentrations in brain tis-
sue usually drop with increasing distance from the tumor core,
and thus the drug concentration is fairly low in the periph-
eral parts of the tumor, where tumor cells inﬁltrate the normal
brain. In these areas, where tumor proliferation is most rapid, the
BTB is relatively intact (Rice et al., 2003; Ningaraj, 2006). Novel
approaches for effective delivery through the BTB of anticancer
agents that circumvent active efﬂux transporters at the BTB, like
P-glycoprotein (Pgp)-mediated efﬂux (Bronger et al., 2005) would
provide neuro-oncologists with effective anticancer agents for the
effective treatment of gliomas thereby increasing patients’ sur-
vival rates. It is known that the BTB is leaky and MRI agents
can penetrate easily, however, the BTB is disrupted only when
the tumor reaches 1 mm in size. This provides an opportunity
for the micro metastatic tumors to survive and spread further. It
has been shown that approximately one-third of patients operated
for gliomas probably have microsatellites distant from primary
tumor core, despite MRI with gadolinium enhancement being the
most sensitive imaging modality for both diagnosis and follow-
up of patients with gliomas (Checkley et al., 2003; Yankeelov
et al., 2005a). In addition, we have validated dynamic contrast
enhancing-magnetic resonance imaging (DCE-MRI) method to
measure changes in permeability following administration of
BTB permeabilizing agent that signiﬁcantly increases the delivery
of gadolinium diethylenetriamine penta-acetic acid (Gd-DTPA)
to detect tumor microsatellites and diffused gliomas (Ningaraj,
2006). Such a validated MRI method would signiﬁcantly inﬂuence
themedical care of glioma patients by providing valuable informa-
tion about the microsatellites and diffused glioma boundary that
may otherwise go undetected. The improved possibility of quan-
titating the BTB defect by MRI may give new information about
tumor pathogenesis or etiology, leading to improved methods in
monitoring the efﬁcacy of treatments in glioma patients.
MATERIALS AND METHODS
CELL LINES
Established cell line representing rat glioma (C6) and mouse
gliomas (GL26) obtained from American Type Culture Collection
were used to study the role of BKCa channels in BTB permeability
regulation. The cancer cells were maintained in minimum essen-
tial medium (MEM; Invitrogen, Carlsbad, USA) containing 10%
fetal bovine serum (Invitrogen, Carlsbad, USA).
ANIMAL STUDY APPROVALS
Animal study approvals were obtained from Vanderbilt Ingram
CancerCenter-InstitutionalAnimalCare andUseCommittee. The
animals were housed at the vivarium facility where tumor implan-
tation procedure was carried out. For MRI scanning, the mice and
rats were transported to the MRI facility in the adjacent building.
INTRACRANIAL TUMOR IMPLANTATION
Nine femaleWistar rats weighing 200–250 g had 2× 105 C6 glioma
cells injected into the basal ganglia. To study increased delivery of
MRI contrast enhancing agent, we used mouse xenograft brain
tumor model. Intracranial tumor implantation was accomplished
by a stereotactic technique as described in our previous studies
(Ningaraj et al., 2002, 2003a,b; Black and Ningaraj, 2006, 2007;
Khaitan et al., 2009). Seven days after tumor implantation, the rats
were imaged using a Varian 4.7 T scanner equipped with a 63-mm
quadrature birdcage coil.
PREPARATION OF RATS FOR DCE-MRI SCANNING AND T1
MEASUREMENT
All imaging was performed on the 9.4 T/20 cm horizontal bore
scanner (Bruker, Billerica, MA, USA) with actively shielded gra-
dients (200 mT/m). Radiofrequency (RF) coils employed was a
35-mm in ID birdcage resonator. Rat was initially anesthetized
with 5% isoﬂurane, which was reduced to 1.5∼2% for mainte-
nance during the experiments, and a catheter inserted in the tail
vein for administration of saline, Gd-DTPA, and 1,3-dihydro-1-
[2-hydroxy-5-(triﬂuoromethyl)phenyl]-5-(triﬂuoromethyl)-2H-
benzimidazol-2-one (NS-1619). Rat was secured in a head
holder with ear bars and a bite bar to prevent head motion,
and placed on a hot water pad to maintain body tempera-
ture. Rectal temperature, heart rate, and blood oxygenation
was continuously monitored during the experiment. Using a
three-plane scout sequence, the central imaging slice was placed
to view the largest lateral extent of the tumor. For anatomic
imaging, T2-weighted multi-slice-multi-echo (MSME) method
was carried out [repetition time (TR) = 4000 ms; echo time
(TE) = 8.6 ms; ﬁeld of view (FOV) = 30 mm × 30 mm; matrix
size = 128 × 128] with 16 slices through the tumor (in-plan voxel
dimension = 0.23 mm × 0.23 mm × 1 mm). T1 map was acquired
with an inversion recovery (IR) true-fast imaging with steady
state precession (FISP) method (TR = 2.85 ms; TE = 1.43 ms;
FOV = 30 mm × 30 mm; matrix size = 128 × 128; thick-
ness = 1 mm; ﬂip angle (α) = 30◦; image frame = 16; range
of inversion time (TI) = 100–2564 ms; TI increment = 154 ms).
Using the fast automatic shimming technique by mapping along
projections (FASTMAP) auto-shimming method, banding arti-
facts, which occasionally appeared in true-FISP images, was
removed by local B0 shimming. A DCE-MRI experiment was per-
formed in glioma rat model with a contrast agent (Gd-DTPA).
Imaging parameters for the IR true-FISP was as described above
except two slices: one was in the largest lateral extent of the tumor
and the other in the rat neck for the measurement of the vascular
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input function (VIF). The VIF was measured in one or both jugu-
lar veins in the rat neck. The IR true-FISP block was repeated 80
times. Following eight baseline scans, the contrast agent mixture
was administered over 5 min via an infusion pump connected to
cannulated tail vein, and immediately followed by a bolus of 1 ml
of saline. For BTB permeability assay potassium channel activa-
tor (NS1619) was administered via tail vein catheter followed by
Gd-DTPA over 5 min through an infusion pump.
UNILATERAL TRANSFER CONSTANT (Ki) MEASUREMENT
After a wash period of 24 h, the same nude rats was used to
determine Ki by quantitative autoradiography (QAR) as described
by us earlier (Asotra et al., 2003). Animals were transferred to
a radiation-secure facility, placed under maintenance anesthesia,
and prepared for constant blood withdrawal as described by Aso-
tra et al. (2003). Brieﬂy, 5 min after the start of the i.v. infusion of
vehicle, NS1619 (30 μg/kg/min for 15 min), 100 μCi/kg of [14C]
sucrose in 1 ml phosphate-buffered saline (PBS) was injected as
an i.v. bolus within 15 s. Rats with abnormal blood gases or blood
pressure were excluded from the study. The Ki (μl/g/min), which
is an initial rate for blood-to-brain transfer of [14C] sucrose was
calculated as described by Ohno et al. (1978). The Ki was deter-
mined for [14C] sucrose in the tumor core, tumor-adjacent brain
tissue, and contralateral normal brain tissue.
VALIDATION OF MRI WITH QAR
For basal BTB permeability (without any BTB modulation)
measurements, nude rats were infused with PBS followed by Gd-
DTPA and DCE-MR images obtained. Brieﬂy, a bolus Gd-DTPA
(0.2 mmol/kg) will be delivered within 5 s via a tail vein catheter.
DCE-MRI data analysis was done via the reference region model
as previously described (Provenzale et al., 2002; Yankeelov et al.,
2005a,b); this analysis returns Ktrans and ve. QAR with the radio-
tracer [14C] sucrose was performed as previously described (Ohno
et al., 1978; Asotra et al., 2003). Ki was determined for four voxels
each from the tumor core and tumor periphery on each slice of
ﬁve contiguous QAR slices. We determined the overall Ki for the
tumor border and tumor core by averaging the results for all ﬁve
slices.
CO-REGISTRATION
The non-invasive, DCE-MRI parameter maps measuring Ktrans
and ve, was co-registered with QAR images on a slice by slice
basis. By this way, we could correlate both global and local
changes in BTB permeability as measured by these two differ-
ent techniques, and validate the use of DCE-MRI measurements.
Correlation of the DCE-MRI measurements to QAR images is
a novel accomplishment, offering opportunities for performing
preclinical anticancer drug screening.
The linear regression curvewas drawn using theKi versus Ktrans
scatter plots and the regression coefﬁcient was calculated, which
indicates signiﬁcance of the correlation between the twomeasures.
A high correlation coefﬁcient between the two different measures
would demonstrate that a non-invasive, clinically relevant DCE-
MRI metric of tissue vessel perfusion-permeability (as assessed by
the reference region model) correlates signiﬁcantly with the QAR
technique. This represents a validation of the reference region
model for the analysis of DCE-MRI data in, at least, the rodent
glioma model that can be translated to a clinical set up.
QUANTITATIVE AUTORADIOGRAPHY
After allowing washout of Gd-DTPA for 24 h the same rats were
subjected to QAR analysis using [14C]-labeled sucrose. Follow-
ing QAR preparation, the regional permeabilities in several tumor
region of interests (ROIs) were estimated by computing the unidi-
rectional transfer constant, Ki as described in previously published
studies (Ohno et al., 1978; Asotra et al., 2003). ROI analysis was
conducted on a set of four pixels from each side of the tumor
rim, from four pixels within the tumor core, and four pixels from
the entire tumor. These same ROIs were then selected from six
contiguous sections and averaged to yield one value for Ki for the
tumor rim, one value for the tumor core, and one value for the
whole tumor average for each animal. These values were then used
for correlation with the DCE-MRI estimate of Ktrans described
above. For comparison to the averaged QAR permeability (Ki)
averaged DCE-MRI permeability (Ktrans) values were obtained for
the tumor rim, tumor core, and the whole tumor. In each case,
voxels were selected and the time courses from each voxel were
averaged to form a single time course which was then analyzed. In
particular, one voxel from each side of the tumor was selected to
construct the tumor rim time course, four contiguous voxels from
the tumor center were selected to produce tumor core time course,
and all enhancing voxels were averaged to produce a single time
course for the whole tumor.
DCE-MRI data analysis as done via the reference region model
to return estimates of Ktrans and ve (the extravascular extracellular
volume fraction) for the tumor rim, tumor core, and whole tumor
average. QAR with [14C] labeled sucrose was performed to obtain
Ki estimates for these same regions. These two measurements were
then compared. A correlation analysis between DCE-MRI (Ktrans)
and QAR (Ki) for the whole tumor was performed. The scatter
plot and regression line was drawn.
EFFECT OF NS-1619 ON BTB PERMEABILITY CHANGES
IN C6-GLIOMA RAT
A signiﬁcant number of brain tumor patients do not respond well
to anticancer agents. This is most likely due to the inability of anti-
cancer agents to cross the BTB and reach cancer cells in the brain
in effective quantities. It has recently been shown that BKCa chan-
nels regulate both BTB permeability and tumor cell proliferation
in rat brain tumors (Ningaraj et al., 2002, 2003a). Therefore, after
validating the MRI with QAR method we investigated whether
NS-1619 increases BTB permeability (Ktrans) and extravascular
extracellular volume fraction (ve) because these parameters have
been applied much to pathology, including brain tumors. Here
we compared the permeability of C6 brain tumors in rats that
received BKCa channel agonist, NS-1619 to C6 brain tumors and
in rats that did not receive NS-1619.
Eight female Wistar rats (weight range, 180–200 g) were
intracranially implanted with 2 × 105 C6 glioma cells as described
earlier, and randomized to saline+Gd-DTPA andNS-1619+Gd-
DTPA groups. We applied the same MRI protocol as described
above for this investigation. Imaging and tumor models were
identical with the exception that the rat in the top frame received
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NS-1619 immediately prior to imaging, while the rat shown in
bottom frame received saline. This indicates that the blood vessels
associated with tumor with treatment are more permeable and/or
more highly perfuse. There is a clear difference in the enhance-
ment (DR1) between the two groups of animals. We showed
that a non-invasive, clinically relevant DCE-MRI metric of tis-
sue vessel perfusion-permeability (as assessed by the reference
region model) is sensitive to changes in blood vessel permeability
following administration of NS-1619 as shown by us previously
(Ningaraj et al., 2002, 2003a; Black and Ningaraj, 2006).
STATISTICS
Data fromprevious studies in rat gliomamodel showed an increase
in BTB permeability from 30.0 ± 1.5 μl/g/min (n = 6,mean ± SE)
in control animals to 70.0 ± 6.0 μl/g/min (n = 6) in NS169-
treated rats. Bothparametric andnon-parametric procedureswere
employed as appropriate; for the validation of MRI by QAR under
the two conditions with and without modulation of potassium
channels, a stratiﬁed Spearman’s rank correlation coefﬁcient was
calculated using SAS software.
TO STUDY WHETHER MRI CONTRAST ENHANCEMENT AROUND BRAIN
TUMOR EDGES CAN BE ACHIEVED BY INJECTING ATP-SENSITIVE
POTASSIUM (KATP) CHANNEL ACTIVATOR
We injected KATP channel opener minoxidil sulfate (MS) intra-
venously (tail vein) for selective and transient opening of BTB to
study whether delivery of Gd-DTPA to leading tumor edges for
enhancing contrast of diffused tumor.
RESULTS
VALIDATION OF MRI WITH QAR
A study performed in rat glioma (C6) model to correlate two dis-
tinctmethods to validateMRImethodwithQARmethod. Figure 1
shows the axial views of the tumor froma central slice of a rat,QAR
FIGURE 1 |Validation of DCE-MRI with QAR method: axial views of the
tumor from a central slice of a rat, QAR image (A), pre-contrast and
10 min post-contrast MR image (B,C).The scatter plot displays the Ki and
Ktrans for the pooled data (D). The r2 is 0.93 (P < 0.05), indicates a signiﬁcant
relationship between Ki and Ktrans (Toda, 2003; Black and Ningaraj, 2004) The
regression line has a slope of 6.33 (E). The correlation coefﬁcient (r2) of 0.93
with P < 0.05, indicates a strong and signiﬁcant relationship between Ki and
Ktrans.
Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs May 2013 | Volume 4 | Article 62 | 4
“fphar-04-00062” — 2013/5/28 — 10:21 — page 5 — #5
Khaitan and Ningaraj Increasing permeability of brain tumors
image (Figure 1A), pre-contrast and 10 min post-contrast MR
image (Figures 1B,C). The scatter plot displays the Ki and Ktrans
for the pooled data. The scatter plot displays the Ki and Ktrans for
the pooled data (Figure 1D). The r2 of 0.93 (P < 0.05), indicates
a signiﬁcant relationship between Ki and Ktrans (Toda, 2003; Black
and Ningaraj, 2004). The regression line with a slope of 6.33 is
shown (Figure 1E). This shows that the non-invasive, clinically
relevant DCE-MRI metric of brain tissue blood vessel perfusion-
permeability (as assessed by the reference region model) correlates
signiﬁcantly with the invasive QAR clinically irrelevant technique.
This represents a validation of the reference region model for the
analysis of DCE-MRI data in, at least, the C6 glioma tumor model,
which could be extrapolated to human brain tumors in a clinical
situation.
NS-1619-INDUCED BTB PERMEABILITY CHANGES IN C6-GLIOMA RAT
Figure 2 shows the increased level of contrast enhancement in
the NS-1619-treated rat as quantiﬁed by DCE-MRI analysis. The
tumor volumes measured by T1-weighted images are approxi-
mately 38.94 and 44.10 mm3 for the top and bottom frames,
respectively. Tumor volumes were computed by manually out-
lining the enhancing region of the brain (for each slice) and
multiplying the number of voxels within each ROI by the voxel
size (0.273 mm3). The increased level of enhancement in the
treated rat was quantiﬁed by DCE-MRI analysis. The control
group Ktrans mean was 1.83 ± 0.59/min, while the treatment
group was 9.20 ± 7.69/min; this difference is signiﬁcant at the
P < 0.05 level. The control group ve mean was 0.16 ± 0.07,
while the treatment group was 0.19 ± 0.07; this difference was
not signiﬁcant.
Magnetic resonance imaging contrast enhancement around
brain tumor edges: we showed that KATP channel opener (MS)
increases Gd-DTPA delivery for enhancement of tumor edges
(Figure 3).
DISCUSSION
Correlation analysis between DCE-MRI and QAR: the quanti-
tative, non-invasive assessment of tumor growth and treatment
response has become an increasingly important and attainable
goal in oncology. Furthermore, the non-invasive measurements
of tissue status have been shown to correlate with disease state,
diagnosis, and treatment response. Thus, there is great and con-
tinuing interest in this methodology. While there is much interest
in the applications of this method to assess tumor growth and
treatment response, there has been comparatively little study of
the correlation of this non-invasive technique with more accepted
(i.e., “gold-standard”) measurements of tumor perfusion (Healy
et al., 1987; Li et al., 2000; Tofts and Kermode, 1991; Tofts, 1997;
Zhu et al., 2000). In fact, at a recent National Cancer Institute
special workshop on translatingDCE-MRImethodology into rou-
tine clinical use, a comment that was repeatedly made was the
necessity of developing appropriate methods of validating the
measurements made by DCE-MRI. In line with this, we conducted
experiments to explore the relationship between the minimally
invasive, clinically relevant measures of vessel perfusion offered
by DCE-MRI to those of the invasive, clinically irrelevant, “gold-
standard” of QAR. In particular, we compared the measurement
FIGURE 2 | Effect of NS-1619 on Ktrans showing the increased level of
contrast enhancement in the NS-1619-treated rat as quantified by
DCE-MRI analysis.The tumor volumes measured byT1-weighted images
are approximately 38.94 and 44.10 mm3 for the top and bottom frames,
respectively. Tumor volumes were computed by manually outlining the
enhancing region of the brain (for each slice) and multiplying the number of
voxels within each ROI by the voxel size (0.273 mm3). The increased level
of enhancement in the treated rat was quantiﬁed by DCE-MRI analysis. The
control group Ktrans mean was 1.83 ± 0.59/min, while the treatment group
was 9.20 ± 7.69/min; this difference is signiﬁcant at the P < 0.05 level. The
control group ve mean was 0.16 ± 0.07, while the treatment group was
0.19 ± 0.07; this difference was not signiﬁcant.
FIGURE 3 | Mouse with glioma (GL-261) was injected with
0.2 mmol/kg of MRI contrast agent Magnevist and DCE-MRI studies
performed (A). After 24 h washout period the same mouse was given
ATP-sensitive potassium (KATP) channel activator, minoxidil sulfate (MS)
prior to Magnevist infusion (B).
of the QAR transfer constant Ki, to the DCE-MRI transfer con-
stant Ktrans in a C6 rat glioma model (Figure 1). Both transfer
constants measure the initial rate for blood-to-brain transfer of a
tracer.
BTB PERMEABILITY MODULATION-CORRELATION OF MRI AND QAR
We showed that a non-invasive, clinically relevant DCE-MRI met-
ric of tissue vessel perfusion-permeability (Figure 2 as assessed by
the reference region model) is sensitive to changes in blood vessel
permeability following administration of BKCa channel activa-
tor NS-1619 (Ningaraj et al., 2002; Black and Ningaraj, 2006). We
have shown that human gliomas and brain tumor ECs overexpress
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potassium channels that can be targeted for increased BTB per-
meability (Ningaraj et al., 2002, 2003b, 2009a; Black and Ningaraj,
2006). It is anticipated that these experiments provide a basis for
targeting ECs that overexpress potassium channels with speciﬁc
activators to permit increasedMRI enhancing agent delivery selec-
tively to brain tumors. Monitoring the outcome of increased MRI
enhancing agents’ delivery to microsatellites and leading tumor
edges in glioma patients would lead to beneﬁcial clinical outcome.
Our ﬁndings may have signiﬁcant impact on CNS drug deliv-
ery by shedding light on the function of the BTB that can be
used to develop novel drug delivery approaches for molecular-
targeted therapy, and further develop methods for non-invasively
imaging BTB permeability changes and the response of glioma to
treatment. Validated MRI permeability measurement technique
may allow patient-speciﬁc therapy to improve clinical outcome in
patients with gliomas. Our research is expected to offer an early
and important translational component to the clinical practice.
When a patient is diagnosed with glioma, deﬁnitively ruling out
the presence or absence of additional lesions in brain is important
for diagnosis and for deciding upon possible surgical manage-
ment. BTB permeability modulation following administration of
potassium channel activators will signiﬁcantly increase the deliv-
ery of Magnevist for greater enhancement of leading tumor edges
as shown in Figure 3, and potentially microsatellites using DCE-
MRI. Furthermore, use of targeted therapies will hopefully lead to
better treatments for this deadly disease. Our present research aims
to develop methods to increase anticancer drug delivery selectively
to glioma cells and retain the drug longer in tumor cells so that
toxicity in the normal brain is prevented. In addition, the early pro-
teomic response data before and after anticancer treatment would
provide valuable insights on differentiating responders from non-
responders based on early tumor response to a drug regimen. This
will augment decisional matrix of clinicians and patients, and
spare patients from unnecessary side effects of cytotoxic drugs.
Nevertheless, further studies are required to validate the DCE-
MRIby co-registering basal andmodiﬁed (increased) permeability
measurements obtained by DCE-MRI and QAR measurements in
human glioma models. This provides a non-invasive means to
measure subtle BTB leakage associated with glioma growth. To
visualize the invasive and diffused glioma for effective treatment,
including surgery, the MRI agents should be efﬁciently delivered
to the tumor edges. In this regard, we showed in a mouse glioma
xenograft, the biochemical modulation of BTB with MS increases
Magnevist delivery to tumor edges (Figure 3).
Enhancing therapeutic efﬁcacy for heterogeneous and aggres-
sive tumors such as gliomas can be achieved by attacking the
cancer cells at different mechanistic pathways simultaneously. In
controlled experiments involving mouse and rat brain tumor
xenografts, we determined the optimal dose and time of adminis-
tration of potassium channel activators (NS1619 and MS). These
activators were found to be non-toxic to animals when evaluated
in human brain tumor xenograft models (Ningaraj et al., 2002,
2003b, 2009a). In our laboratory, the studies are in progress by
employing DCE-MRI to detect and measure microsatellites and
diffused glioma edges in normal brain following transient potas-
sium channel activator-induced BTB permeability increase to
Gd-DTPA. In addition, we are investigating the effect of KCNMA1
(codes for alpha subunit of BKCa channels) down-regulation on
BTB permeability in human brain tumor model. We seek to
demonstrate whether tumor developed using U87 MG cells with
KCNMA1 down-regulation fail to elicit similar BTB permeabil-
ity increase to Gd-DTPA following NS169 infusion compared to
that of the wild type tumor. Since we have already validated the
DCE-MRI with QAR BTB permeability measurements, now work
is underway to quantitatively measure the BTB permeability in
metastatic brain tumor models developed with intracranial injec-
tionof breast and lungmetastatic cancer cell lineswith andwithout
KCNMA1 knockdown. With this strategy, we seek to study the
role of KCNMA1 in BTB permeability regulation in human brain
tumor xenograft models.
In conclusion, it is anticipated that this research will provide
a basis for targeting primary and metastatic brain cancer cells
and the BTB that overexpress potassium channels with agents that
activate potassium channels. Thus we might increase penetration
of anticancer drugs and MRI contrast enhancing agents selec-
tively to brain tumors in patients resulting in beneﬁcial clinical
outcomes.
ACKNOWLEDGMENTS
We thank Vanderbilt Ingram Cancer Center (VICC) for Research
Grant to Dr. Nagendra S. Ningaraj, and technical staff at MRI
Core facility for facilitating this study. We also thank the Ameri-
can Cancer Society and the Georgia Cancer Coalition for awarding
research grants to Nagendra S. Ningaraj.
REFERENCES
Asotra, K., Ningaraj, N., and Black, K.
L. (2003). Measurement of blood–
brain and blood–tumor barrier
permeabilities with [14C]-labeled
tracers. Methods Mol. Med. 89,
177–190.
Black, K. L., and Ningaraj, N. S. (2004).
Modulation of brain tumor capillar-
ies for enhanced drug delivery selec-
tively to brain tumor. Cancer Control
11, 165–173.
Black, K. L., and Ningaraj, N. S. (2006).
Method for Using Potassium Chan-
nel Agonists for Delivering a Medi-
cant to an Abnormal Brain Region
and/or a Malignant Tumor. US Patent
7018979.
Black, K. L., and Ningaraj, N. S. (2007).
Method for Inducing Selective Cell
Death of Malignant Cells by Activa-
tion of Calcium-activated Potassium
Channels (KCa). US Patent 7211561.
Bronger, H., Konig, J., Kopplow,
K., Steiner, H. H., Ahmadi, R.,
Herold-Mende, C., et al. (2005).
ABCCdrug efﬂuxpumps andorganic
anion uptake transporters in human
gliomas and the blood–tumor bar-
rier. Cancer Res. 65, 11419–11428.
Buie, L. W., and Valgus, J. (2008).
Bevacizumab: a treatment option for
recurrent glioblastoma multiforme.
Ann. Pharmacother. 42, 1486–1490.
Checkley, D., Tessier, J. J., Wedge, S.
R., Dukes, M., Kendrew, J., Curry,
B., et al. (2003). Dynamic contrast-
enhanced MRI of vascular changes
induced by the VEGF-signalling
inhibitor ZD4190 in human tumour
xenografts. Magn. Reson. Imaging 21,
475–482.
Cucullo, L. N., Marchi, N., Marroni,
M., Fazio, V., Namura, S., and Jani-
gro, D. (2003). Blood–brain barrier
damage induces release of alpha2-
macroglobulin. Mol. Cell. Proteomics
2, 234–241.
Demeule, M., Regina, A., Annabi, B.,
Bertrand, Y., Bojanowski, M. W., and
Béliveau, R. (2004). Brain endothe-
lial cells as pharmacological targets
in brain tumors. Mol. Neurobiol. 30,
157–83.
Doubrovin, M., Ponomarev, V.,
Serganova, I., Soghomonian, S.,Mya-
gawa, T., Beresten, T., et al. (2003).
Development of a new reporter
gene system – ds Red/xanthine
phosphoribosyltransferase-
xanthine for molecular imaging
of processes behind the intact blood–
brain barrier. Mol. Imaging 2,
93–112.
Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs May 2013 | Volume 4 | Article 62 | 6
“fphar-04-00062” — 2013/5/28 — 10:21 — page 7 — #7
Khaitan and Ningaraj Increasing permeability of brain tumors
Fortin, D., Desjardins, A., Benko,
A., Niyonsega, T., and Boudrias,
M. (2005). Enhanced chemother-
apy delivery by intraarterial infusion
and blood–brain barrier disruption
in malignant brain tumors: the
Sherbrooke experience. Cancer 103,
2606–2615.
Healy, M. E., Hesselink, J. R., Press,
G. A., and Middleton, M. S. (1987).
Increased detection of intracranial
metastases with intravenous Gd-
DTPA. Radiology 165, 619–624.
Inamura, T., and Black, K. L. (1994).
Bradykinin selectively opens blood–
tumor barrier in experimental brain
tumors. J. Cereb. Blood Flow Metab.
14, 862–870.
Jaeger, L. B., Banks, W. A., Varga, J.
L., and Schally, A. V. (2005). Antag-
onists of growth hormone-releasing
hormone cross the blood–brain bar-
rier: a potential applicability to
treatment of brain tumors. Proc.
Natl. Acad. Sci. U.S.A. 102, 12495–
12500.
Kemper, E. M., Boogerd, W., Thuis,
I., Beijnen, J. H., and van Tellingen,
O. (2004). Modulation of the blood–
brain barrier in oncology: therapeu-
tic opportunities for the treatment of
brain tumors? Cancer Treat. Rev. 30,
415–423.
Khaitan, D., Chandna, S., Arya, M.
B., and Dwarakanath, B. S. (2006).
Differential mechanisms of radiosen-
sitization by 2-deoxy-D-glucose in
the monolayers and multicellular
spheroids of a human glioma cell
line. Cancer Biol. Ther. 5, 1142–
1151.
Khaitan, D., Sankpal, U., Weksler,
B., Meister, E. A., Romero, I. A.,
Couraud, P. O., et al. (2009). Role of
KCNMA1 gene in breast cancer inva-
sion and metastasis to brain. BMC
Cancer 9:258. doi: 10.1186/1471-
2407-9-258
Kinoshita,M.,MMcDannold,N., Jolesz,
F. A., and Hynynen, K. (2006). Tar-
geted delivery of antibodies through
the blood–brain barrier by MRI-
guided focused ultrasound. Biochem.
Biophys. Res. Commun. 340, 1085–
1090.
Lee, S. W., Kim, W. J., Park, J. A., Choi,
Y. K., Kwon, Y. W., and Kim, K.
W. (2006). Blood–brain barrier inter-
faces and brain tumors. Arch. Pharm.
Res. 29, 265–275.
Li, K. L., Zhu, X. P., Water-
ton, J., and Jackson, A. (2000).
Improved 3D quantitative mapping
of blood volume and endothe-
lial permeability in brain tumors.
J. Magn. Reson. Imaging 12,
347–357.
Liu, X., Chang, Y., Reinhart, P. H.,
Sontheimer, H., and Chang, Y.
(2002). Cloning and characterization
of glioma BK, a novel BK channel
isoform highly expressed in human
glioma cells. J. Neurosci. 22, 1840–
1849.
Liu, Y., Hashizume, K., Samoto, K.,
Sugita, M., Ningaraj, N., Aso-
tra, K., et al. (2001). Repeated,
short-term ischemia augments
bradykinin-mediated opening of
the blood–tumor barrier in rats
with RG2 glioma. Neurol. Res. 23,
631–640.
Mathieu, V., De Neve, N., Le Mercier,
M., Dewelle, J., Gaussin, J. F.,
Dehoux, M., et al. (2008). Combin-
ing bevacizumab with temozolomide
increases the antitumor efﬁcacy of
temozolomide in a human glioblas-
toma orthotopic xenograft model.
Neoplasia 10, 1383–1392.
Ningaraj, N. S. (2006). Drug deliv-
ery to brain tumors: challenges and
progress. Expert Opin. Drug. Deliv. 3,
499–509.
Ningaraj, N. S., Rao,M., and Black, K. L.
(2003a). Calcium-dependent potas-
sium channels as a target protein
for modulation of the blood–brain
tumor barrier. Drug News Perspect.
16, 291–298.
Ningaraj, N. S., Rao, M. K., and
Black, K. L. (2003b). Adeno-
sine 5′-triphosphate-sensitive potas-
sium channel-mediated blood–brain
tumor barrier permeability increase
in a rat brain tumor model. Cancer
Res. 63, 8899–8911.
Ningaraj, N. S., Rao, M., Hashizume,
K., Asotra, K., and Black, K.
L. (2002). Regulation of blood–
brain tumor barrier permeability by
calcium-activated potassium chan-
nels. J. Pharmacol. Exp. Ther. 301,
838–851.
Ningaraj, N. S., Salimath, B. P.,
Sankpal, U. T., Perera, R., and
Vats, T. (2007). Targeted brain
tumor treatment-current per-
spectives. Drug Target Insights 2,
197–207.
Ningaraj, N. S., Sankpal, U. T., Khai-
tan, D., Meister, E. A., and Vats, T.
(2009a). Activation of KATP channels
increases anticancer drug delivery to
brain tumors and survival. Eur. J.
Pharmacol. 602, 188–19.
Ningaraj, N. S., Sankpal, U. T., Khai-
tan, D., Meister, E. A., and Vats, T.
(2009b). Modulation of KCa chan-
nels increases anticancer drug deliv-
ery to brain tumors and prolongs
survival in xenograft model. Cancer
Biol. Ther. 8, 1924–1933.
Ohno, K., Pettigrew, K. D., and
Rapoport, S. I. (1978). Lower limits of
cerebrovascular permeability to non-
electrolytes in the conscious rat. Am.
J. Physiol. 235, H299–H307.
Pardridge, W. M. (2003). Blood–brain
barrier drug targeting: the future of
brain drug development. Mol. Interv.
3, 90–105, 51.
Pardridge, W. M. (2004). Intravenous,
non-viral RNAi gene therapy of brain
cancer. Expert Opin. Biol. Ther. 4,
1103–1113.
Provenzale, J. M., Wang, G. R., Bren-
ner, T., Petrella, J. R., and Sorensen,A.
G. (2002). Comparison of permeabil-
ity in high-grade and low-grade brain
tumors using dynamic susceptibility
contrast MR imaging. AJR Am. J.
Roentgenol. 178, 711–716.
Quencer, R. M., and Neuwelt, E. A.
(2002). Advances in the understand-
ing of the blood–brain barrier in
neuro-oncology. AJNR Am. J. Neu-
roradiol. 23, 1807–1810.
Rautioa, J., and Chikhale, P. J. (2004).
Drug delivery systems for brain
tumor therapy. Curr. Pharm. Des. 10,
1341–1353.
Rice, A., Michaelis, M. L., Georg, G.,
Liu, Y., Turunen, B., and Audus, K.
L. (2003). Overcoming the blood–
brain barrier to taxane delivery for
neurodegenerative diseases and brain
tumors. J.Mol. Neurosci. 20, 339–343.
Rich, J. N., and Bigner, D. D. (2004).
Development of novel targeted ther-
apies in the treatment of malignant
glioma. Nat. Rev. Drug Discov. 3,
430–446.
Sontheimer, H. (2004). Ion channels
and amino acid transporters support
the growth and invasion of primary
brain tumors. Mol. Neurobiol. 29,
61–71.
Toda,M. (2003). Immuno-viral therapy
as a new approach for the treatment
of brain tumors. Drug News Perspect.
16, 223–229.
Tofts, P. S. (1997). Modeling tracer
kinetics in dynamic Gd-DTPA MR
imaging. J. Magn. Reson. Imaging 7,
91–101.
Tofts, P. S., and Kermode, A.
G. (1991). Measurement of the
blood–brain barrier permeability and
leakage space using dynamic MR
imaging. 1. Fundamental con-
cepts. Magn. Reson. Med. 17,
357–367.
Yankeelov, T. E., Kasisomayajula, K.,
Ningaraj, N., Price, R. R., and
Gore, J. C. (2005a). “Correlation
between quantitative autoradiogra-
phy and the reference region model
of DCE-MRI,” in ISMRM Thirteenth
Annual Meeting, 7–13 May, Miami
Beach, FL, USA, p. 2749.
Yankeelov, T. E., Luci, J. J., Lepage,
M., Li, R., Debusk, L., Lin, P. C.,
et al. (2005b). Quantitative pharma-
cokinetic analysis of DCE-MRI data
without an arterial input function: a
reference region model. Magn. Reson.
Imaging 23, 519–529.
Zhang, Y., Boado, R. J., and Pardridge,
W. M. (2003). In vivo knockdown of
gene expression in brain cancer with
intravenous RNAi in adult rats. J.
Gene Med. 5, 1039–1045.
Zhu, X. P., Li, K. L., Kamaly-Asl, I.
D., Checkley, D. R., Tessier, J. J.,
Waterton, J. C., et al. (2000). Quan-
tiﬁcation of endothelial permeability,
leakage space, and blood volume in
brain tumors using combined T1 and
T2* contrast-enhanced dynamic MR
imaging. J. Magn. Reson. Imaging 11,
575–585.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 18 January 2013; paper pend-
ing published: 22 March 2013; accepted:
22 April 2013; published online: 29 May
2013.
Citation: Khaitan D and Ningaraj
NS (2013) Targeting potassium chan-
nels for increasing delivery of imaging
agents and therapeutics to brain tumors.
Front. Pharmacol. 4:62. doi: 10.3389/
fphar.2013.00062
This article was submitted to Frontiers in
Pharmacology of Anti-Cancer Drugs, a
specialty of Frontiers in Pharmacology.
Copyright © 2013 Khaitan and Ningaraj.
This is an open-access article dis-
tributed under the terms of the Creative
Commons Attribution License, which
permits use, distribution and reproduc-
tion in other forums, provided the origi-
nal authors and source are credited and
subject to any copyright notices concern-
ing any third-party graphics etc.
www.frontiersin.org May 2013 | Volume 4 | Article 62 | 7
